Medicare GLP-1 Bridge: $50 Copay Starts July 1, 2026 — But Only Through 2027

The Trump administration's CMS, led by Dr. Mehmet Oz, is rolling out the Medicare GLP-1 Bridge starting July 1, 2026. This temporary demonstration program caps out-of-pocket costs at $50 per month for certain GLP-1 weight-loss drugs for Medicare Part D enrollees with obesity. While the $50 copay is a significant reduction from list prices that can exceed $1,000 per month, the program has critical limitations: it only runs through December 31, 2027, covers a restricted list of drugs (named in the demonstration as Wegovy and two others not yet public), and importantly, the $50 copay does not count toward the Part D deductible or the annual out-of-pocket threshold. This means beneficiaries may face additional cost exposure if they need other medications during the year. The Bridge is a subsidy model, not a price control – CMS is essentially paying manufacturers a negotiated rate to keep costs low for patients, without permanently lowering the underlying prices. This approach leaves patients vulnerable to the program's expiration and does not address the root cause of high drug prices: lack of government negotiation power. The temporary nature of the Bridge contrasts with proposals like the Treat and Reduce Obesity Act (TROA), which would make GLP-1 coverage permanent under Medicare Part D and would require CMS to negotiate prices. Without permanent coverage, millions of seniors could lose access after 2027, and the program does nothing to lower list prices for uninsured or underinsured populations.